Tag Archives: vandetanib

FDA Panel Supports the Use of Vandetanib in Medullary Thyroid Cancer

An FDA advisory committee reported that they supported the use of AstraZeneca’s vandetanib for the treatment of patients with medullary thyroid cancer (MTC).   However, they also indicated the drug should be reserved for patients who are experiencing symptoms of their … Continue reading

Posted in Cancer, Thyroid Cancer | Tagged , , | Comments Off on FDA Panel Supports the Use of Vandetanib in Medullary Thyroid Cancer